Tina Wang | Director, HTA programme and Strategic Partnership
Center for Innovation in Regulatory Science

I am Director of the HTA Programme and Strategic Partnerships at the Centre for Innovation in Regulatory Science (CIRS), an independent, not-for-profit organisation, where I lead global HTA strategy, policy research and international engagement.

My work focuses on the intersection of regulatory decision-making, HTA, evidence generation and patient access. Through comparative policy research and international benchmarking, I examine how regulatory, HTA and reimbursement systems are evolving, how healthcare archetype, decision processes differ across markets, and how reforms reshape decision-making, evidence expectations, medicines development and patient access. I work closely with senior decision-makers and stakeholders across global regulatory agencies, HTA and payer bodies, industry, academia and patient organisations. By bringing these perspectives together in a neutral environment, I lead international research and policy dialogue on shared challenges and emerging priorities in HTA.

A distinctive focus of my work is China’s rapidly evolving pharmaceutical innovation, regulatory and reimbursement landscape, including the globalisation of China-origin medicines and the implications for international development, evidence and access strategies.